16 October 2016

KWM Firsts - Advising on breakthrough impact investments

King & Wood Mallesons advised UBS Wealth Management, the world’s largest global wealth manager, on the final closing of its $471 million UBS Oncology Impact Fund.

UBS’ Oncology Impact Fund is the first of its kind in the healthcare sector and the largest global impact investing opportunity that’s come to market to date. It is an initiative aimed at developing new cancer treatments, financing academic research and access to cancer care in developing countries.

Oncology is a perfect theme for social impact requiring a large investment. The market for cancer drugs is expected to grow faster than for any other disease, due to populations ageing in developed countries and an expanding middle class in emerging markets with better access to care. Oncology is the largest and fastest growing therapeutic area in terms of drug development activity, representing approximately a quarter of total research spend.

Impact investing aims to generate a defined positive social impact as well as a competitive return. It is an attractive area for investors who wish to align their portfolios with their values. It is potentially a highly significant source of capital for oncology, given cancer's wide-ranging social implications.

The technical innovation of this fund is ground-breaking. It will make a substantial impact to the research and development of cancer treatments and improve access to cancer care around the world. Moreover, the success of the fundraising shows the increasing appetite among investors in investment opportunities that can have a tangible social impact and deliver financial returns at the same time.

Our International Funds team has been at the forefront of the market since its inception, and we have acted as legal counsel on many of the largest and most complex funds transactions in recent years. The record sum raised for the Fund is a milestone for the bank’s work in sustainable investing and for the impact investing industry as a whole.

Lead partner

Ajay Pathak, KWM London

Media Contact

Share on LinkedIn Share on Facebook Share on Twitter
    You might also be interested in

    KWM gains Dr. Peter Polke as Counsel thus strengthening its M&A and private equity practice and continuing the successful growth of the past 3 years.

    24 March 2020

    KWM has advised Ninestar Corporation on the investment in the German tonerdumping.de Orth & Baer GmbH

    02 March 2020

    KWM has advised ISVision (Huangzhou) Technology Co, Ltd. on the acquisition of EHR GmbH & Co. KG, a specialist of high-precision measurement.

    07 February 2020

    KWM has advised Sino German M&A Service GmbH on the acquisition of business operations of SolMic Research GmbH out of insolvency.

    28 January 2020

    This site uses cookies to enhance your experience and to help us improve the site. Please see our Privacy Policy for further information. If you continue without changing your settings, we will assume that you are happy to receive these cookies. You can change your cookie settings at any time.

    For more information on which cookies we use then please refer to our Cookie Policy.